Addex Therapeutics stock analysis
Addex Therapeutics (0QNV) Share Price & Analysis
0QNV Stock Chart & Stats
- Day’s Range
- CHF 0.02 - CHF 0.02
- 52-Week Range
- CHF 0.02 - CHF 0.06
- Previous Close
- CHF 0.02
- Volume
- N/A
- Average Volume (3M)
- 679
- Market Cap
- CHF 2.75M
- Enterprise Value
- CHF 4.26M
- Total Cash (Recent Filing)
- CHF 767.33K
- Total Debt (Recent Filing)
- CHF 77.50K
- Price to Earnings (P/E)
- ―
- Beta
- 0.02
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces fixed financial obligations and near-term solvency pressure while the company funds clinical development. This gives Addex more flexibility to pursue partnerships, milestones, and pipeline decisions without the additional constraint of substantial debt service.
Extended Funding Runway
The additional financing and stated runway provide more time to advance multiple clinical and preclinical programs, pursue partnerships, and reach value-relevant milestones. This can reduce immediate financing disruption, although continued development still depends on disciplined cash management.
Expanded Proprietary Pipeline
Regaining full rights restores strategic control over a broad GABAB PAM portfolio and allows Addex to develop assets internally, partner them, or pursue different indications. Combined with advancing candidates, this increases optionality for future monetization and portfolio prioritization.
Bears Say
Deep, Persistent Unprofitability
Severe and continuing losses show that the current clinical-stage model has not yet produced economically sustainable earnings. Without approved products or dependable collaboration income, ongoing deficits can erode equity and increase reliance on future financing or strategic transactions.
Negative Cash Generation
Persistent cash consumption means Addex cannot currently fund its operations and pipeline solely from internally generated resources. This places greater importance on external capital, partnerships, or asset monetization and can force development sequencing around available funding rather than scientific priorities.
Funding Required For Pipeline Advancement
The need to secure financing before starting planned chronic cough studies creates a direct execution constraint on pipeline progress. Delayed funding could postpone clinical entry, extend the period before potential milestone creation, and increase dependence on investors or partners to advance additional programs.
Addex Therapeutics News
0QNV FAQ
What was Addex Therapeutics’s price range in the past 12 months?
What is Addex Therapeutics’s market cap?
When is Addex Therapeutics’s upcoming earnings report date?
How were Addex Therapeutics’s earnings last quarter?
Is Addex Therapeutics overvalued?
Does Addex Therapeutics pay dividends?
What is Addex Therapeutics’s EPS estimate?
How many shares outstanding does Addex Therapeutics have?
What happened to Addex Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Addex Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Addex Therapeutics Stock Smart Score
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Mark Dyer
- Employees
- 3
- Website
- www.addextherapeutics.com
- Address
- Chemin des Mines, 9, Geneva, GE, 1202, CH
Addex Therapeutics (0QNV) Earnings & Revenues
0QNV Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with management highlighting $2.8 million of financing, a cash runway into Q4 2027, regained rights to the GABAB PAM platform, strong preclinical chronic cough data, and continued progress across the Neurosterix and Addex pipelines. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash usage, continued net losses, an increase in Addex's share of Neurosterix's loss, and the need to secure financing before starting chronic cough IND-enabling studies.
View all GB:0QNV earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 10 |
| Technical Analysis | 4 | 0 | 1 |
| Moving Averages | 2 | 1 | 9 |
